ClinicalTrials.gg
CompletedNCT00148460Updated Oct 29, 2013

Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction

A Phase 3 interventional study of TNK-tPA and rt-PA in Myocardial Infarction, sponsored by Boehringer Ingelheim. Completed at 18 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-10-29.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Myocardial Infarction by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Myocardial Infarction · Boehringer Ingelheim.

Started
2001
with 1 other
Phase 3
6 of 12
none open now
Registered
1st of 12
by date

Among the 12 studies in Myocardial Infarction by Boehringer Ingelheim, this one is one of 2 that started in 2001, is one of 6 in phase 3, and was the 1st registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

None of the 12 studies in Myocardial Infarction by Boehringer Ingelheim is open now. The open studies under Myocardial Infarction, anywhere →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Myocardial Infarction by Boehringer Ingelheim as a file.
02

Study summary

The objective of this trial was to compare the efficacy and safety of a single bolus of TNK-tPA (tenecteplase, Metalyse®) compared with rt-PA (alteplase, Actilyse®) in Asian patients.

Read the detailed description

This was a randomized (1:1), open-label, multi-center, active-control, parallel-group study to compare the efficacy and safety of TNK-tPA (tenecteplase, Metalyse®) with that of accelerated rt-PA (alteplase, Actilyse®) in Asian patients with AMI. The primary endpoint (TIMI 3 Flow) and the secondary endpoint (TIMI frame count) were evaluated in a blinded manner in the core laboratory.

Patients eligible for the trial who met all inclusion and exclusion criteria and who gave their informed consent were randomized to one of two treatment groups (i.e. TNK-tPA or accelerated rt-PA).

The study period totaled 30-37 days and included baseline, randomisation, study drug administration, in-hospital follow-up and thirty-day follow-up.

Coronary angiography was performed at 90 minutes after the start of study drug administration. 12-lead electrocardiograms (ECGs) were obtained before randomization, between 60 to 75 minutes and 180 ± 15 minutes after the start of study drug administration, and at hospital discharge.

If the patient showed rapid and progressive hemodynamic deterioration before 90 minutes, rescue PTCA or other appropriate interventions should be performed at the discretion of the treating physician.

Following the analysis of TIMI flow and frame count at each study center, the results were carefully recorded on the CRFs. This data was stored on a compact disk or a film and labeled with the subject's study I.D. number. It was then sent with the summary worksheets and ECGs to the Angiographic Core Laboratory located at the Leuven Coordinating Center (LCC) of the University Hospital Gasthuisberg (Leuven, Belgium) for central evaluations.

Study Hypothesis:

The null hypothesis tested was that there was no difference between the two treatment groups: TNK-tPA (Tenecteplase, Metalyse®) and accelerated rt-PA (Actilyse®), against the alternative that there was a difference.

Comparison(s):

The primary endpoint of the study was TIMI 3 flow at 90 minutes after start of thrombolytic therapy, angiograms were evaluated in a blinded manner in a core laboratory.

03

Conditions studied

  • Myocardial Infarction
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >= 18 and \<= 75 years.
  2. Asian origin.
  3. Ischemic discomfort >= 30 minutes in duration.
  4. Onset of acute myocardial infarction (AMI) symptoms within 6 hours prior to randomization.
  5. A twelve lead (ECG) with one of the following:

    • ST segment elevation >= 0.1 mV in two or more limb leads; or
    • >= 0.2 mV in two or more contiguous precordial leads indicative of AMI.
  6. Ability to give .

Exclusion criteria

Exclusion Criteria:

  1. Previous coronary artery bypass grafting (CABG) surgery.
  2. Cardiogenic shock (e.g. systolic blood pressure [SBP] \< 90 mmHg).
  3. Systolic blood pressure (SBP) >= 180 mmHg and/or diastolic blood pressure (DBP) >= 110 mmHg during current admission on one reliable measurement prior to randomization.
  4. Inability to undergo cardiac catheterization.
  5. Significant bleeding disorder either at present or within the past 6 months.
  6. Major surgery, of a parenchymal organ, or significant trauma within 3 months.
  7. Any minor head trauma and/or any other trauma that occurred after onset of current myocardial infarction.
  8. Use of heparin, GPIIb/IIIa antagonists or other anticoagulants within the last 2 weeks.
  9. Any known history of stroke or or central nervous system structural damage (i.e. neoplasm, aneurysm, intracranial surgery).
  10. Prolonged cardiopulmonary resuscitation (> 10 minutes) within 2 weeks.
  11. Pregnancy, lactation or parturition within the previous 30 days. Women of must have had a negative pregnancy test and must have used a medically accepted method of (i.e. uterine device, surgical sterilisation, progestogens alone).
  12. Previous treatment with TNK-tPA (tenecteplase).
  13. Inability to follow protocol and comply with follow-up.
  14. Drug abuse within the last year.
  15. Participation in another clinical trial within the previous 30 days.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
270 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The percentage of patients with thrombolysis in myocardial infarction (TIMI) grade 3 flow in the infarct-related artery (IRA)

    Time frame: at 90 minutes after the start of thrombolytic treatment

Secondary outcomes

  1. Infarct-related artery patency

    Time frame: at 90 minutes

  2. The percentage of subjects with ST-segment resolution

    Time frame: at 60 and 180 minutes

  3. Mortality

    Time frame: 30-days

  4. Safety

  5. The effects of TNK-tPA on coagulation and fibrinogenolysis (at selected clinical sites)

07

Study locations

18 sites
  • Beijing An Zhen Hospital
    Beijing, 100029, China
  • Beijing University
    Beijing, 100044, China
  • Beijing Friendship Hospital
    Beijing, 100050, China
  • Beijing Xuan Wu Hospital
    Beijing, 100050, China
  • Bejing Tongren Hospital
    Beijing, 100730, China
  • Center Hospital of Dalian
    Dalian, 116033, China
  • Center Hospital of Jinan
    Jinan, 250013, China
  • Fudan University
    Shanghai, 200032, China
  • People's Hospital of Liaoning Province
    Shenyang, 110015, China
  • The University of Hong Kong, Cardiology Division
    Hong Kong, Hong Kong
  • Dongsan Medical Center
    Jung-Ku, 700711, Korea, Republic of
  • Chunnam University Hospital
    Kwang-Ju, 501757, Korea, Republic of
  • Dong-A University Hospital
    Pusan, 602715, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 100744, Korea, Republic of
  • Yonsei University Severance Hospital
    Seoul, 120752, Korea, Republic of
  • Seoul Joongang Hospital
    Seoul, 138736, Korea, Republic of
  • A-Jou University Hospital
    Suwon, 443721, Korea, Republic of
  • Wonju Christian Hospital (Yonsei University Hosp)
    Wonju, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2001 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2005
First posted
Sep 8, 2005
Start
Mar 2001
Completion
Feb 2006
Last update
Oct 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Oct 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00148460
First posted
Sep 8, 2005
Start date
Mar 2001
Completion
Feb 2006
Last update
Oct 29, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · Boehringer Ingelheim Shanghai
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tenecteplase · Tissue Plasminogen Activator

Start the discussion